{
    "clinical_study": {
        "@rank": "129350", 
        "brief_summary": {
            "textblock": "This study was advocated by institute of Basic Research in Clinical Medicine,China Academy\n      of Chinese Medical Sciences in October 2011.\n\n      It was funded by China major scientific and technological specialized specialized project\n      for 'significant new formulation of net drugs'.\n\n      Kudiezi(Yueanxin) is kind of Chinese Medicine injiection used for treating corinary heart\n      diswese\u3001angina pectoris and stroke in many Chinese hospitals.\n\n      The purpose of this study is to determine adverse drug events or adverse drug reaction in\n      large sample size 30,000 patients."
        }, 
        "brief_title": "Safety Study of Kudiezi(Yueanxin,a Chinese Medicine Injection)Used in Hospitals in China", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Coronary Heart Disease", 
            "Angina Pectoris", 
            "Stroke"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Angina Pectoris", 
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease", 
                "Heart Diseases", 
                "Stroke"
            ]
        }, 
        "detailed_description": {
            "textblock": "It is very common that Chinese Medicine Injection used in hospitals in mainland\n      China.However safety problems rose in recent years.There could be many uncertain factors\n      influence Chinese Medincine Injection in clinical practice.\n\n      Safety surveillance on Chinese Medincine injection is an important problem that needs to be\n      sorted out through large sample observational dtudy.\n\n      A registry study for Kudiezi(Yueanxin) injection safety surveillance with 30000 patients\n      will be conducted form Jan.2012 to Dec.2015.\n\n      Eligiblity crteria Patients who will use Kudiezi(Yueanxin) injection in selected hospitals.\n\n      Date will be collected in four aspects by four different forms as following:\n\n      Form A(blue):demographic information ;Form B(yellow):adverde drug events/reaction;Form\n      C(white):extracted information from hodpiral information system and laboratory information\n      system."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Patients using Kudiezi(Yueanxin) injection from 2012 to 2014\n\n        Exclusion Criteria:\n\n        none"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "An anticpcipated sample size was caculated in this study,about 30000.Patients using\n        Kudiezi injection from 2012 to 2014 in more than 20 hospital."
            }
        }, 
        "enrollment": {
            "#text": "30000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01781676", 
            "org_study_id": "RSCMI-\u2167"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 13, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "state": "Beijing", 
                    "zip": "100700"
                }, 
                "name": "Institute of Basic Research in Clinical Medicine"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_groups": "1", 
        "official_title": "Registry Study Intensive Hospital Monitoring Protocol of Kudiezi Injection ( Yueanxin ) 's Clinical Safety", 
        "overall_official": {
            "affiliation": "China  Academy of Chinese Medical Sciences", 
            "last_name": "Xie Y Ming, BA", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "China: State Administration of Traditional Chinese Medicine of the People's Republic of China", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "All patients will be measured and assessed at the time Kudiezi(Yueanxin) is adminnistered to them until they discharge.Patients using Kudiezi(Yueanxin) will be registered on a regisration form including disease background, Kudiezi(Yueanxin)'s adminidtration,and extraction information from hospital information system.An adverse event or drug adverse reaction form also will be used to describe any doubted symptoms or signs from patients.A judgment will be made by doctors directly and a further analysis will be conducted by researchers to decide those potential side effects of Kudiezi(Yueanxin).", 
            "measure": "Number of participants with adverse events;incidence of Kudiezi(Yueanxin)'ADRs and identify factors that contributed to the occurrence of the adverse reaction", 
            "safety_issue": "Yes", 
            "time_frame": "to assess Kudiezi(Yueanxin)'s 'adverse event' and 'drug adverse reaction' during patients' hospital stay,administration information of Kudiezi will be registered every day.The registry procedure will last 3 years only for patients using Kudiezi."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01781676"
        }, 
        "responsible_party": {
            "investigator_affiliation": "China  Academy of Chinese Medical Sciences", 
            "investigator_full_name": "Yanming Xie", 
            "investigator_title": "Deputy Director", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "China  Academy of Chinese Medical Sciences", 
        "sponsors": {
            "collaborator": {
                "agency": "Longhua Hospital", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "China  Academy of Chinese Medical Sciences", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "14 Days", 
        "verification_date": "April 2013"
    }
}